Teva Launches Authorized Generic of Minastrin® 24 Fe

Teva Pharmaceutical Industries has announced the launch of the Authorized Generic of Minastrin^® 24 Fe¹ (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) mg/20 mcg in the U.S.

The Authorized Generic of Minastrin^® 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy.

This Authorized Generic of Minastrin^® 24 Fe adds to Teva’s existing portfolio of more than 50 oral contraceptives. In the U.S., one of every two oral contraceptive prescriptions is filled with a product marketed by Teva.²

Minastrin^® 24 Fe had annual sales of approximately $361 million in the U.S. according to IMS data as of December 2016.